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 35 
Condensation 36 
Small-for-gestational-age infants from low-risk, term pregnancies are at increased risk of 37 
serious neonatal morbidity regardless of gestational age at birth.  38 
 39 
Short title 40 
Small for gestational age infants at term gestation and serious neonatal outcomes. 41 
 42 
Implications and Contributions 43 
• This study was conducted to ascertain the outcomes for small for gestational age 44 
(SGA) infants in a low risk maternal cohort from an Australian tertiary centre.  45 
• SGA infants had significantly worse perinatal outcomes compared to appropriately 46 
grown cohorts particularly if birth occurred at early term.  47 
• The results highlight the considerable risk SGA infants face even in a low risk cohort 48 
and underscore the importance of screening in pregnancy. The results also suggest 49 
that birth before 39+0 weeks should be avoided wherever possible given the increased 50 
risk of adverse outcomes.  51 
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Abstract   53 
Background: Small-for-gestational age (SGA) infants (birthweight <10th centile) are at 54 
increased risk of perinatal complications but are frequently not identified antenatally, 55 
particularly in low risk women delivering at term (>37 weeks gestation). This is compounded 56 
by the fact that late pregnancy ultrasound is not the norm in many jurisdictions for this cohort 57 
of women. We thus investigated the relationship between birthweight <10th centile and 58 
serious neonatal outcomes in low risk women at term.  59 
Objective(s): We aimed to determine whether there is a difference of obstetric and perinatal 60 
outcomes for SGA infants, subdivided into 5th - <10th centile and <5th centile cohorts 61 
compared to an appropriate-for-gestational age (AGA) (birthweight 10th - 90th centile) group 62 
at term.  63 
Study Design: This was retrospective analysis of data from the Mater Mother’s Hospital in 64 
Brisbane, Australia for women who birthed between January 2000 and December 2015.  65 
Women with multiple pregnancy, diabetes mellitus, hypertension, pre-term birth, major 66 
congenital anomalies and large for gestational age infants (>90th centile for gestational age) 67 
were excluded. SGA infants were subdivided into 2 cohorts - infants with birthweights 5th - 68 
<10th centile and those <5th centile. Serious composite neonatal morbidity (SCNM) was 69 
defined as any of the following: Apgar score ≤3 at 5 minutes, respiratory distress syndrome, 70 
acidosis, admission into the Neonatal Intensive Care Unit (NICU), stillbirth or neonatal 71 
death.  Univariate and multivariate analysis were performed using generalized estimating 72 
equations to compare obstetric and perinatal outcomes for SGA infants compared to AGA 73 
controls.  74 
Results: The final study comprised 95,900 infants. 5.0% were between the 5th and <10th 75 
centiles for birthweight and 4.3% were <5th centile. The rate of SCNM was 11.1% in the 76 
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control group, 13.7% in the 5th and <10th centile and 22.6% in the <5th centile cohorts 77 
respectively. Even after controlling for confounders, both the 5th - <10th centiles and <5th 78 
centile cohorts were at significantly increased risk of SCNM compared to controls (OR 1.25, 79 
95% CI 1.15-1.37 and OR 2.20, 95% CI 2.03-2.39 respectively). Infants with birthweights 80 
<10th centile were more likely to have severe acidosis at birth, 5 minute Apgar score <3 and 81 
to be admitted to NICU. The SCNM was higher in infants <5th centile compared to those in 82 
the 5th - <10th centile cohort (OR 1.71, 95% CI 1.52-1.92). The odds of perinatal death 83 
(stillbirth and neonatal death) were significantly higher in both small-for-gestational age 84 
groups than controls. After stratification for gestational age at birth, the composite outcome 85 
remained significantly higher in both small-for-gestational-age cohorts and was highest in the 86 
<5th centile group at 37+0 - 38+6 weeks (OR 3.32, 95% CI 2.87-3.85). The risk of perinatal 87 
death was highest for infants <5th centile at 37+0 - 38+6 weeks (OR 5.50, 95% CI 2.33-88 
12.98).  89 
Conclusion(s): SGA infants from term, low risk pregnancies are at significantly increased 90 
risk of mortality and morbidity when compared to AGA infants. Although this risk is 91 
increased at all gestational ages in infants <5th centile for birthweight, it is highest at early 92 
term gestation. Our findings highlight that early term birth does not necessarily improve 93 
outcomes and emphasize the importance of identifying this cohort of infants.  94 
 95 
Key Words: Small for gestational age, fetal growth restriction, neonatal morbidity, neonatal 96 
mortality, stillbirth, term gestation, perinatal outcome, perinatal mortality, perinatal morbidity    97 
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Main Text 99 
Introduction  100 
Compared to preterm cohorts, overall perinatal complications in term small for gestational 101 
age (SGA) infants (defined as birth weight <10th centile for gestation) are lower and tend to 102 
be at the milder end of the spectrum.1, 2 In high income countries >60% of non-anomalous 103 
SGA births occur at term with evidence that compared to appropriate for gestational age 104 
(AGA) controls reduced birthweight is associated with an increased risk of morbidity and 105 
mortality.3, 4 The increased risk is partly due to the proportion of SGA infants that are truly 106 
growth restricted secondary to placental dysfunction. Indeed in low risk pregnancies, 107 
placental malperfusion and dysfunction accounts for a population attributable risk of 25% for 108 
SGA infants.5 Clinical identification of SGA fetuses late in pregnancy is difficult, with 109 
physical examination and symphysis fundal height (SFH) assessment limited by a number of 110 
factors including maternal habitus and fetal lie. Furthermore, unlike women with known risk 111 
factors (hypertension, diabetes mellitus, previous fetal growth restriction etc.), routine 112 
ultrasound to assess fetal growth is generally not performed in low risk women unless there 113 
are concerns about fetal size on clinical examination.  114 
From a healthcare burden perspective, the vast majority of SGA infants are born at term 6 115 
often from uncomplicated, low risk pregnancies. The difficulty however, is defining what 116 
constitutes a “low risk” cohort as there are many maternal medical, demographic and 117 
psychosocial factors that are associated with an increased risk of adverse outcomes. Clearly if 118 
this population were to be defined by the absence of all possible risk factors this would result 119 
in an artificially low number of women that would be considered “normal” or “low risk”. 120 
Such an approach would be divorced from clinical reality. Notwithstanding the difficulty in 121 
defining this cohort, some investigators have suggested that excluding women with diabetes 122 
mellitus and hypertension is reasonable given their relatively high prevalence in pregnancy.4 123 
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More specifically, the objectives were to evaluate outcomes for infants with birth weight <5th 124 
centile and 5th - <10th centiles stratified for gestational age at birth (≥37+0 weeks - 38+6 125 
weeks, ≥39+0 weeks – 40+6 weeks and >41 weeks).  126 
 127 
128 
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Materials and Methods  129 
This was a retrospective cohort study of women who birthed between January 2000 and 130 
December 2015 at the Mater Mother’s Hospital in Brisbane, Australia using previously 131 
prospectively collected data. Maternal demographic, intrapartum and perinatal outcome 132 
information were collected from the hospital’s maternity database and cross-referenced with 133 
the maternal and fetal medicine and neonatal databases to ensure robust data ascertainment. 134 
The Mater Mother’s Hospital is a major tertiary center in Queensland with a birth rate of 135 
approximately 10,500 per annum, making it the largest maternity hospital in Australia. 136 
Approval for this study was granted by the institution’s Human Research Ethics Committee 137 
(Reference number HREC/14/MHS/37).  138 
We included all women with non-anomalous singleton, term pregnancies with a recorded 139 
birth weight. Gestational age was calculated using the last menstrual period or earliest 140 
ultrasound examination, or by correlation of both. Birth weight centiles were calculated with 141 
reference to previously published Australian standards.7 AGA was defined as a birth weight 142 
of 10th - 90th centile. The SGA cohort was subdivided into two categories: SGA1 (birth 143 
weight 5th - <10th centiles) and SGA2 (birth weight <5th centile). Women with multiple 144 
gestations, diabetes mellitus (either pre-existing or gestational), hypertension (either pre-145 
existing, pregnancy induced or pre-eclampsia), congenital fetal malformations and pre-term 146 
birth (<37 weeks) were excluded.  147 
Demographic data analyzed included maternal age, ethnicity (Caucasian, Asian, Indigenous 148 
or other), parity, marital status, smoking status, alcohol consumption and body mass index 149 
(BMI). Indigenous ethnicity was defined as women who identified as being of Aboriginal or 150 
Torres Strait Islander origin. Intrapartum outcomes collected included onset of labor (induced 151 
or spontaneous) and mode of birth (spontaneous vaginal delivery (SVD), instrumental, 152 
elective cesarean, emergency cesarean for non-reassuring fetal status (NRFS), or emergency 153 
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cesarean for other indications).  Univariate analysis was first performed to identify significant 154 
potential confounders. 155 
Neonatal outcomes analyzed included gestational age at birth, birth weight, Apgar score <3 at 156 
5 minutes, presence of significant respiratory distress (as defined by the attending 157 
neonatologist), perinatal death, neonatal death, stillbirth, acidosis at birth and admission to 158 
the neonatal intensive care unit (NICU). Perinatal death was defined as stillbirths and 159 
neonatal death combined. Only stillbirths confirmed to have occurred >37 weeks gestation 160 
were included in the analysis. Neonatal death was defined as death within 28 days of birth. 161 
Acidosis was defined as cord pH <7, lactate ≥6 mmol/L or cord base excess ≤-12mmol/L. 162 
Serious composite neonatal morbidity (SCNM) was defined as any of the following: Apgar 163 
score ≤3 at 5 minutes, respiratory distress syndrome, acidosis, admission into NICU, stillbirth 164 
or neonatal death.   165 
Statistical analysis  166 
Data integrity was assessed using a year by year analysis to identify inconsistencies of 167 
reporting between years. Where data integrity was questionable with sudden drops in 168 
outcomes that could not be accounted for by change in policy or treatment, those variables 169 
were excluded from any analysis. Efforts were made to correct missing and data entry errors 170 
through searches of individual patient records. Where data were collected with different 171 
degree of outcomes between years, these variables were collapsed into dichotomous variables 172 
to indicate whether the outcome occurred or not. Where only the outcomes were recorded, 173 
after discussion with data custodians it was determined that it was reasonable to assume that 174 
missing data indicated that the outcome had not occurred. 175 
Descriptive analysis was performed using Mann Whitney U Tests for continuous variables 176 
and categorical variables compared using Chi-square test.  All continuous variables were 177 
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tested for normality using a Shapiro-Wilk W Test and deemed to be non-normally 178 
distributed. Subsequently data are reported as median (Inter-quartile Range (IQR)) or as the 179 
number of observations with the percentage of total. Univariate and multivariate analysis was 180 
performed using Generalized Estimating Equations to adjust for the correlation between 181 
mothers who birthed more than once within the study period. Multivariate analysis was 182 
adjusted for sex, maternal age and BMI at delivery, ethnicity, parity, smoking status and 183 
mode of birth. All statistical analyses were conducted using StataCorp. 2015. Stata Statistical 184 
Software: Release 14. College Station, TX: StataCorp LP. 185 
 186 
 187 
 188 
189 
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Results  190 
Between 2000 and 2015 there were 137,398 women who birthed at the Mater Mother’s 191 
Hospital. After excluding 41,498 women the final cohort (Figure 1) comprised of 95,900 192 
women and infant dyads. Infants with birthweights 5th - <10th centiles (SGA1) and <5th 193 
centile SGA2) constituted 5.0% (4,748/95,900) and 4.3% (4,135/95,900) of the total cohort 194 
respectively.  195 
Both the SGA1 and SGA2 cohorts were found to significantly differ from the AGA cohort 196 
with respect to maternal age, ethnicity, parity, marital status, smoking status and maternal 197 
BMI. They were more likely to be young (maternal age <20 years), of Asian, Indigenous and 198 
other ethnicity, nulliparous and smoke, and less likely to be married and obese. When the 199 
SGA1 and SGA2 cohorts were compared, the odds of maternal age <20 years, Asian and 200 
Indigenous ethnicity, nulliparity and smoking status were higher in the SGA2 cohort. (Table 201 
1)    202 
For intrapartum outcomes, both the SGA1 and SGA2 cohorts were significantly more likely 203 
than the AGA cohort to have an instrumental or emergency cesarean for non-reassuring fetal 204 
status (“fetal distress”). The odds of requiring induction of labor (IOL) was higher in the 205 
SGA2 compared to the AGA cohort and higher in the SGA2 compared to the SGA1 group. 206 
The odds of spontaneous vaginal delivery (SVD) were, however, lower in the SGA2 cohort 207 
when compared to both the AGA and the SGA1 cohorts. (Table 2)  208 
There was no difference in median gestation at birth for either of the SGA sub-cohorts 209 
compared to AGA controls.  The odds of severe acidosis at birth, very low (<3) 5 minute 210 
Apgar score and NICU admission were significantly higher in the SGA1 and SGA2 cohorts 211 
even after controlling for confounders (sex, maternal age and BMI, parity, ethnicity, smoking 212 
and mode of birth). The odds of stillbirth or neonatal death were however not different 213 
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between the SGA1 and SGA2 cohorts.  The odds of serious composite neonatal morbidity 214 
(SCNM) was highest in the SGA2 cohort (OR 2.20, 95% CI 2.03-2.39) compared to the AGA 215 
controls. The odds of the SCNM was also higher in the SGA2 compared to the SGA1 cohort 216 
(OR 1.71, 95% CI 1.52-1.92). (Table 3) 217 
The risk of perinatal death (stillbirth and neonatal death) was substantially higher in both 218 
SGA cohorts compared to the control group. The SGA1 cohort had an almost 3-fold 219 
increased odds of perinatal death (OR 2.62, 95% CI 1.45-4.72), more than 4-fold increased 220 
odds of neonatal demise (OR 4.34, 95% CI 1.46-12.95) and more than 2-fold increased risk 221 
of stillbirth (OR 2.22, 95% CI 1.10-4.49) compared to the AGA cohort whilst the SGA2 222 
cohort had even greater odds for the same outcomes [perinatal death (OR 3.91, 95% CI 2.27-223 
6.73), neonatal death (OR 5.70, 95% CI 2.03-16.01) and stillbirth (OR 3.45, 95% CI 1.82-224 
6.53)] respectively. (Table 3) 225 
Following stratification of neonatal outcomes by gestational age, the odds of SCNM 226 
remained significantly increased in both SGA groups compared to controls.  The SGA2 227 
cohort had higher odds of SCNM than the SGA1 cohort at 37+0 - 38+6 weeks (OR 2.48, 228 
95% CI 2.02-3.04) and at 39+0 - 40+6 weeks (OR 1.54, 95% CI 1.30-1.83). For both cohorts, 229 
the odds of NICU admission was highest at early term (37+0 - 38+6 weeks) and subsequently 230 
decreased with rising gestation. The odds of stillbirth (OR 5.40, 95% CI 1.96-14.83), and 231 
overall perinatal death (OR 5.50, 95% CI 2.33-12.98) was highest in the SGA2 cohort at 232 
37+0 - 38+6 weeks. (Table 4)  233 
234 
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Comment  235 
Principal findings 236 
The results from this large Australian study demonstrates that in low risk pregnancies, 237 
outcomes for SGA infants born at term are significantly worse compared to an AGA cohort. 238 
Specifically, newborns with birthweight <5th centile (SGA2) had a doubling of the SCNM 239 
(22.6% vs. 11.1%) while infants with birthweight 5th – 10th centile (SGA1) had 23% (13.7% 240 
vs. 11.1%) increase in adverse outcomes. Regression analyses to control for confounders 241 
showed that the SCNM was >2 fold higher in the SGA2 cohort. We also found, that although 242 
the risk of SCNM was greatest at early term gestation regardless of SGA sub-cohort, this risk 243 
remained elevated even at term and post term gestation. Importantly our results indicate that 244 
the risk of stillbirth was >5-fold and >3-fold at early term and term respectively and that the 245 
odds of neonatal death in the SGA2 cohort increased from 37+0 - 38+6 weeks (OR 5.94, 95% 246 
CI 1.20-29.34) to >41 weeks (OR 12.97, 95% CI, 1.53-109.80) albeit with wide confidence 247 
intervals. 248 
Our findings also show that the odds of emergency cesarean for non-reassuring fetal status 249 
was significantly greater in both the SGA1 and SGA2 cohorts with the highest odds in the 250 
SGA2 cohort. This is an important finding given that there is significant neonatal morbidity 251 
(neonatal encephalopathy, respiratory distress, acidosis, admission to the neonatal intensive 252 
care unit) associated with intrapartum hypoxia. Furthermore, rapid delivery by emergency 253 
cesarean for non-reassuring fetal status is associated with poorer neonatal outcomes 254 
compared to uncomplicated vaginal birth.8 In Australia, emergency cesarean rates for “fetal 255 
distress” range from 11-16% 9 reflecting trends seen in other high income countries. 256 
Alongside the increased risk of perinatal death, the possibility of hypoxia related brain 257 
injured individuals requiring a lifetime of care, intra-partum fetal compromise continues to 258 
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represent a major burden for healthcare providers around the world, with SGA infants a 259 
particularly vulnerable cohort for this specific complication.    260 
Our study represents the largest cohort study published to date investigating serious neonatal 261 
outcomes in a population without major risk factors (hypertension and diabetes mellitus) for 262 
aberrant fetal growth. Collectively, our findings and that two another recent large 263 
publications from North America,4 10 including one published in an earlier issue of this 264 
Journal 4 provide robust evidence of the perinatal risks that pregnancies with SGA infants 265 
face, even at term. Furthermore, when identification of SGA infants is made on the basis of 266 
ultrasound measurements, the odds of perinatal morbidity is more than doubled in infants 267 
with an estimated fetal weight <5th centile, regardless of whether the SGA diagnosis is made 268 
in early third trimester or within 28 days of the delivery, findings that concur with the results 269 
of our study.11 Given that such women make up the majority of pregnancies in most 270 
jurisdictions 6 the imperative for prenatal identification of SGA fetuses is obvious, as it is 271 
now clear that regardless of gestation, overall perinatal outcomes for SGA infants are worse 272 
compared to their appropriately grown counterparts and this dichotomy is even more 273 
pronounced if fetal growth restriction is present.12, 13 Additionally, the risk of term perinatal 274 
death is substantially increased with low birth weight 3 further underlining the critical 275 
importance of prenatal identification given that early term delivery could be one potential 276 
strategy of mitigating this risk, notwithstanding the potential neonatal morbidity associated 277 
with this option.  278 
The evidence regarding ultrasound detection of SGA fetuses is confusing and conflicting 279 
with some studies showing a lack of benefit14 15 whilst others demonstrating detection rates 280 
>50%.16 17 18 Furthermore, Cochrane reviews do not demonstrate an advantage with the use 281 
of either routine late pregnancy ultrasound or umbilical artery Doppler assessment in low-risk 282 
populations.19, 20 Moreover, it is also unclear whether a single late pregnancy measurement of 283 
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fetal biometry or assessment of growth velocity is superior for the identification of an SGA 284 
fetus.  A recent study from North America found that there was no difference in SGA 285 
detection rates when single biometry was compared with serial measurements with only 286 
modest impact on screening performance when maternal risk factors including diabetes 287 
mellitus and hypertension were accounted for.21 This study also demonstrated that fetal 288 
biometry measured within 2 weeks of pre-determined gestational age cut-offs (<32 weeks 289 
and <36 weeks) did not improve detection rates for SGA fetuses. Conversely, another study 290 
showed that although third trimester biometry provided poor to moderate detection of SGA 291 
fetuses, a shorter compared to a longer ultrasound to delivery interval provided better 292 
prediction.22 Others ultrasound studies have suggested that the fetal cerebroplacental ratio 293 
(CPR) is a promising marker for identification of fetuses that have suboptimal growth.23 24 25, 294 
26
 
27A low CPR particularly in SGA fetuses is associated with an increased risk of stillbirth28 295 
and other adverse perinatal outcomes.29 It also appears to be an independent predictor of 296 
intrapartum fetal compromise, acidosis at birth and neonatal unit admission in term infants.30 297 
31
 298 
Although a recent review comparing planned early delivery with expectant management at 299 
term for suspected fetal compromise failed to show a difference in perinatal mortality, 300 
neonatal morbidity or neurodevelopment disability32 there is emerging evidence to suggest 301 
that when accompanied by careful surveillance and planned delivery, rates of adverse 302 
outcomes in SGA infants can be reduced.33 Currently the American Congress of Obstetricians 303 
and Gynecologists recommends delivery by 39 weeks for infants with fetal growth 304 
restriction, without other risk factors 12 whilst the Royal College of Obstetricians and 305 
Gynaecologists in the United Kingdom recommend delivery by 37 weeks.34  This difference 306 
in recommendations for timing of delivery reflects the paucity of good data to guide 307 
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management. The results from our study however would support a policy of deferring 308 
delivery of SGA infants in a low risk cohort of women until 39+0 weeks.  309 
The main limitations of this study relate to its retrospective nature and its single institution 310 
focus. We also used population charts rather than customized ones when defining our 311 
cohorts. In our view this approach was however resonable given the data from the 312 
Intergrowth-21st 35 and other studies36 suggesting that customized charts were not superior in 313 
identifying infants at-risk of adverse outcomes. We however acknowledge that although 314 
some investigators37 suggest that the use of customized charts better identifies SGA infants, 315 
others urge caution38 noting that detection rates are no different whatever charts are used. 316 
Furthermore, whilst it is clear that the risk of adverse outcomes is maximum at extremes of 317 
size,2 the incremental risk appears to commence at higher birth weight centiles than the cut-318 
offs we have chosen.39  We were also not able to ascertain the number of women in whom 319 
there were antenatal concerns and had increased surveillance of wellbeing. As a consequence 320 
of this, we were unable to establish the proportion of women who had planned birth (IOL or 321 
cesarean) because of either clinical concerns regarding fetal size or an ultrasound confirmed 322 
SGA fetus.  Additionally, data regarding socioeconomic status, prenatal education, specific 323 
intrapartum (chorioamnionitis, abruption etc.) and neonatal complications (necrotising 324 
enterocolitis etc.) were not consistently or reliably recorded and hence not reported in this 325 
study. The strengths of our study include the very large sample size from a tertiary institution 326 
with clear evidence based protocols guiding management providing a “real world” view of 327 
outcomes. Furthermore, it is unlikely that our results were influenced by a Hawthorne effect 328 
given that all patient data were collected contemperaneously in the absence of enrollment of 329 
participants in any clinical studies. We also chose components of the composite morbidity to 330 
reflect not only very poor condition at birth (Apgar <3 and severe acidosis, severe respiratory 331 
distress and admission to the NICU) but also mortality (stillbirth and neonatal death). 332 
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Conclusions and implications for clinical practice 333 
In conclusion, the results presented in this paper provide further evidence that SGA infants 334 
from term uncomplicated pregnancies have significantly increased morbidity and mortality 335 
rates when compared to AGA infants, with the greatest risk seen in infants <5th centile 336 
regardless of gestation at birth. The evidence for increased morbidity and mortality seen in 337 
SGA infants both in this and other studies, in our view highlights the importance of prenatal 338 
identification of this group. Although the optimum management algorithm post detection is 339 
yet to be determined, identification of a vulnerable cohort such as this allows potentially 340 
closer surveillance as well a comprehensive discussion with women regarding ongoing risks 341 
and all management options including early term birth, induction of labour or planned 342 
cesarean. Our findings also support the need for large randomized controlled studies to 343 
ascertain firstly, the optimum screening gestation and technique for SGA fetuses (single late 344 
pregnancy ultrasound, serial biometry measurements and/or incorporating the fetal CPR, 345 
placental biomarkers etc.), and secondly the optimum gestation for delivery to mitigate this 346 
risk.  347 
 348 
 349 
 350 
 351 
 352 
 353 
 354 
 355 
 356 
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Table 1: Maternal Demographics 506 
Maternal 
Characteristic AGA, n=87017 
SGA, n=8883 SGA1 vs. 
AGA  
SGA2 vs. 
AGA  
SGA2 vs. 
SGA1 SGA1, 
n=4748 
SGA2, 
n=4135 
Maternal age, years 
<20 2117/87006 (2.4%) 
184/4748 
(3.9%) 
209/4134 
(5.1%) 
1.60 
(1.37-
1.87)c 
2.07 
(1.79-
2.40)c 
1.32 
(1.07-
1.62)b 
20-34 63127/87006 (72.6%) 
3471/4748 
(73.1%) 
3035/4134 
(73.4%) 
1.03 
(0.97-
1.10) 
1.06 
(0.98-
1.13) 
1.02 
(0.93-
1.12) 
≥35 21762/87006 (25.0%) 
1093/4748 
(23.0%) 
890/4134 
(21.5%) 
0.89 
(0.83-
0.96)b 
0.82 
(0.76-
0.88)c 
0.92 
(0.83-
1.01) 
Ethnicity  
Caucasian 67713/86959 (77.9%) 
3141/4744 
(66.2%) 
2547/4130 
(61.7%) 
0.56 
(0.53-
0.60)c 
0.46 
(0.43-
0.50)c 
0.82 
(0.75-
0.90)c 
Asian 10430/86959 (12.0%) 
957/4744 
(20.2%) 
934/4130 
(22.6%) 
1.84 
(1.71-
1.99)c 
2.12 
(1.96-
2.29)c 
1.16 
(1.05-
1.29)b 
Indigenous 1395/86959 (1.6%) 
111/4744 
(2.3%) 
136/4130 
(3.3%) 
1.46 
(1.20-
1.79)c 
2.03 
(1.69-
2.45)c 
1.41 
(1.09-
1.82)b 
Other 7421/86959 (8.5%) 
535/4744 
(11.3%) 
513/4130 
(12.4%) 
1.35 
(1.23-
1.49)c 
1.49 
(1.35-
1.64)c 
1.11 
(0.97-
1.26) 
Nulliparous  40915/87006 (47.0%) 
2734/4748 
(57.6%) 
2595/4133 
(62.8%) 
1.54 
(1.45-
1.63)c 
1.91 
(1.80-
2.03)c 
1.26 
(1.15-
1.37)c 
Married  77170/85861 (89.9%) 
4033/4678 
(86.2%) 
3444/4056 
(84.9%) 
0.71 
(0.65-
0.78)c 
0.65 
(0.60-
0.71)c 
0.90 
(0.80-
1.02) 
Smoker  12570/87017 (14.5%) 
940/4748 
(19.8%) 
1023/4135 
(24.7%) 
1.45 
(1.35-
1.56)c 
1.90 
(1.76-
2.05)c 
1.33 
(1.20-
1.47)c 
Alcohol 7865/87017 (9.0%) 
399/4748 
(8.4%) 
347/4135 
(8.4%) 
0.93 
(0.83-
1.03) 
0.93 
(0.84-
1.04) 
1.01 
(0.87-
1.17) 
BMI (kg/m2) ≥30 8234/84095 (7.8%) 
298/4566 
(6.5%) 
270/3917 
(6.9%) 
0.64 
(0.57-
0.72)c 
0.69 
(0.60-
0.78)c 
1.06 
(0.89-
1.26) 
 507 
Data is presented as n (%); Univariate Odds Ratio (95% Confidence Interval). ap-value < 508 
0.05; bp-value <0.01; cp-value <0.001 509 
 510 
AGA: appropriate for gestational age (birthweight 10th-90th centile); BMI: body mass index; 511 
SGA: small for gestational age (birthweight <10th centile for gestational age); SGA1: 512 
birthweight 5th - <10th centiles for gestational age; SGA2: birthweight <5th centile for 513 
gestational age. 514 
 515 
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Table 2: Intrapartum Outcomes 517 
Intrapartum 
Outcome 
AGA, n=  
87017 
SGA, n=8883 SGA1 vs 
AGAd  
SGA2 vs. 
AGAd  
SGA2 vs. 
SGA1d  SGA1, 
n=4748 
SGA2, n= 
4135 
Gestational Age (weeks) 
37+0 – 38+6 25029/87017 
(28.8%) 
1308/4748 
(27.6%) 
1081/4135 
(26.1%) 
0.94 
(0.88-
1.00)a 
0.86 (0.80-
0.93)c 
0.92 (0.84-
1.02) 
39+0 – 40+6 49175/87017 
(56.5%) 
2660/4748 
(56.0%) 
2353/4135 
(56.9%) 
0.98 
(0.92-
1.04) 
1.02 (0.96-
1.09) 
1.04 (0.96-
1.14) 
≥41 12813/87017 
(14.7%) 
780/4748 
(16.4%) 
701/4135 
(17.0%) 
1.15 
(1.06-
1.24)b 
1.20 (1.10-
1.30)c 
1.04 (0.93-
1.16) 
IOL 22770/68698 
(33.2%) 
1240/3964 
(31.3%) 
1202/3509 
(34.3%) 
0.95 
(0.89 – 
1.02)  
1.09 (1.01 
– 1.17)a 
1.15 (1.04-
1.26)b 
Method of Birth  
SVD 
46679/86990 
(53.7%) 
2672/4745 
(56.3%) 
2214/4134 
(53.6%) 
1.04 
(0.98-
1.09)  
0.92 (0.87-
0.98)b 
0.89 (0.82-
0.96)b 
Instrumental 
11484/86990 
(13.2%) 
725/4745 
(15.3%) 
657/4134 
(15.9%) 
1.19 
(1.10-
1.29)c 
1.25 (1.15-
1.36)c 
1.05 (0.94-
1.18) 
Elective Cesarean 
17642/86990 
(20.3%) 
717/4745 
(15.1%) 
527/4134 
(12.8%) 
0.75 
(0.70-
0.81)c 
0.57 (0.52-
0.62)c 
0.81 (0.72-
0.91)c 
Emergency 
Cesarean 
11184/86990 
(12.9%) 
631/4745 
(13.3%) 
736/4134 
(17.8%) 
1.04 
(0.95-
1.13) 
1.47 (1.36-
1.60)c 
1.42 (1.27-
1.59)c 
Emergency 
Cesarean – NRFS 
3657/86990 
(4.2%) 
336/4745 
(7.1%) 
450/4134 
(10.9%) 
1.74 
(1.55-
1.95)c 
2.78 (2.51 
-3.09)c 
1.60 (1.38 
– 1.86)c  
Emergency 
Cesarean - Other 
7527/86990 
(8.7%) 
295/4745 
(6.2%) 
286/4134 
(6.9%) 
0.70 
(0.62-
0.79)c 
0.78 (0.70-
0.88)c 
1.12 (0.95-
1.33) 
 518 
Data is presented as n (%); dUnivariate Odds Ratio (95% Confidence Interval). ap-value < 519 
0.05; bp-value <0.01; cp-value <0.001 520 
 521 
AGA: appropriate for gestational age (birthweight 10th-90th centile); IOL: Induction of Labor; 522 
NRFS: non-reassuring fetal status; SGA: small for gestational age (birthweight <10th centile 523 
for gestational age); SGA1: birthweight 5th - <10th centiles for gestational age; SGA2: 524 
birthweight <5th centile for gestational age; SVD: spontaneous vaginal delivery.  525 
 526 
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Table 3: Neonatal outcomes  528 
Neonatal 
Outcome 
AGA, 
n=87017  
SGA, n=8883 
SGA1 vs. 
AGAd 
SGA2 vs. 
AGAd 
SGA2 vs. 
SGA1d  SGA1, 
n=4748 
SGA2, 
n=4135 
Gestational Age 
(Weeks) 39 (38-40) 39 (38-40) 39 (38-40) NA NA NA 
Birth Weight (g) 3450 (3210-3690) 
2870 (2730-
2980) 
2630 (2470-
2785) NA NA NA 
Apgar Score ≤3 
@ 5 min  
142/86865 
(0.2%) 
16/4734 
(0.3%) 
19/4124 
(0.5%) 
1.93 (1.12-
3.33)a 
2.22 (1.29-
3.81)b 
1.24 (0.60-
2.57) 
Respiratory 
Distress  
6301/87017 
(7.2%) 
345/4748 
(7.3%) 
405/4135 
(9.8%) 
1.04 (0.93-
1.17) 
1.41 (1.26 -
1.58)c 
1.32 (1.12-
1.54)b 
Perinatal Death  94/87017 (0.1%) 
15/4748 
(0.3%) 
20/4135 
(0.5%) 
2.62 (1.45-
4.72)b 
3.91 (2.27-
6.73)c 
1.46 (0.69-
3.09) 
Neonatal Death  19/86942 (0.02%) 
5/4738 
(0.1%) 
6/4121 
(0.2%) 
4.34 (1.46-
12.95)b 
5.70 (2.03-
16.01)b 
1.22 (0.32-
4.63) 
Stillbirth  75/87017 (0.1%) 
10/4748 
(0.2%) 
14/4135 
(0.3%) 
2.22 (1.10-
4.49)a 
3.45 (1.82 -
6.53)c 
1.56 (0.64-
3.80) 
Acidosis  2442/87017 (2.8%) 
225/4748 
(4.7%) 
257/4135 
(6.2%) 
1.48 (1.28-
1.72)c 
1.80 (1.56-
2.07)c 
1.21 (0.99-
1.47)  
NICU  3740/87017 (4.3%) 
285/4748 
(6.0%) 
562/4135 
(13.6%) 
1.41 (1.24-
1.61)c 
3.25 (2.94-
3.61)c 
2.22 (1.90-
2.60)c 
SCNM  9660/87017 (11.1%) 
650/4748 
(13.7%) 
933/4135 
(22.6%) 
1.25 (1.15-
1.37)c 
2.20 (2.03 -
2.39)c 
1.71 (1.52-
1.92)c 
  529 
Data is presented as n (%) or Median (Interquartile Range); dAdjusted Odds Ratio (95% 530 
Confidence Intervals) - Adjusted for sex, maternal age and BMI, ethnicity, parity, smoking 531 
status and mode of birth. ap-value < 0.05; bp-value <0.01; cp-value <0.001 532 
 533 
AGA: appropriate for gestational age (birthweight 10th-90th centile); SGA: small for 534 
gestational age (birthweight <10th centile for gestational age); SGA1: birthweight 5th - <10th 535 
centiles for gestational age; SGA2: birthweight <5th centile for gestational age; NICU: 536 
Neonatal Intensive Care Unit; SCNM: Serious Composite Neonatal Morbidity 537 
 538 
 539 
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Table 4: Neonatal Morbidity Stratified by Gestational Age 542 
Neonatal 
Outcome 
Gestational Age 37+0 – 38 
+6 Weeks  
Gestational Age 39+0 – 40 
+6 Weeks  Gestational Age >41 Weeks  
SGA1 
vs. 
AGAd  
SGA2 
vs. 
AGAd  
SGA2 
vs. 
SGA1d  
SGA1 
vs. 
AGAd  
SGA2 
vs. 
AGAd  
SGA2 
vs. 
SGA1d  
SGA1 
vs. 
AGAd  
SGA2 
vs. 
AGAd  
SGA2 
vs. 
SGA1d  
Apgar Score 
≤3 @ 5 min 
2.77 
(1.21-
6.34)a 
5.57 
(2.65-
11.70)c 
1.92 
(0.71-
5.20) 
1.95 
(0.88-
4.31) 
1.42 
(0.57-
3.55) 
0.83 
(0.26-
2.59) 
0.58 
(0.08-
4.41) 
NA NA 
Respiratory 
Distress  
0.92 
(0.75-
1.13) 
1.61 
(1.32-
1.96)c 
1.73 
(1.32-
2.28)c 
1.12 
(0.94 -
1.32) 
1.35 
(1.15-
1.59)c 
1.17 
(0.94-
1.47) 
1.08 
(0.83-
1.42) 
1.23 
(0.95-
1.61) 
1.17 
(0.80-
1.70) 
Perinatal 
Death  
2.61 
(1.00-
6.84)  
5.50 
(2.33-
12.98)c 
1.91 
(0.60-
6.07) 
3.39 
(1.58-
7.27)b 
3.16 
(1.45-
6.88)b 
0.90 
(0.33-
2.46) 
NA 
2.56 
(0.52-
12.66) 
NA 
Neonatal 
Death  
2.67 
(0.33 -
21.86)  
5.94 
(1.20-
29.34)a 
2.08 
(0.18-
24.41) 
7.69 
(1.93-
30.58)b 
2.19 
(0.31-
15.54) 
0.26 
(0.03-
2.29) 
NA 
12.97 
(1.53-
109.80)a 
NA 
Stillbirth  
2.58 
(0.87 -
7.65)  
5.40 
(1.96-
14.83)b 
1.88 
(0.49-
7.16) 
2.56 
(1.00-
6.58)  
3.40 
(1.46-
7.94)b 
1.36 
(0.42-
4.40) 
NA NA NA 
Acidosis  
1.61 
(1.14-
2.26)b 
2.50 
(1.81 -
3.45)c 
1.46 
(0.94-
2.26) 
1.41 
(1.15-
1.72)b 
1.71 
(1.41-
2.08)c 
1.23 
(0.94 -
1.62) 
1.55 
(1.18-
2.03)b 
1.57 
(1.19-
2.06)b 
1.04 
(0.72-
1.51) 
NICU  
1.55 
(1.26-
1.91)c 
5.13 
(4.35 -
6.04)c 
3.20 
(2.48-
4.13)c 
1.32 
(1.08-
1.61)b 
2.82 
(2.41-
3.30)c 
2.08 
(1.62-
2.66)c 
1.30 
(0.97-
1.75) 
1.87 
(1.43-
2.43)c 
1.44 
(0.98-
2.11)  
SCNM  
1.29 
(1.10 -
1.51)b 
3.32 
(2.87-
3.85)c 
2.48 
(2.02-
3.04)c 
1.21 
(1.06-
1.38)b 
1.92 
(1.71 -
2.16)c 
1.54 
(1.30-
1.83)c 
1.26 
(1.03-
1.55)a 
1.58 
(1.30-
1.92)c 
1.28 
(0.97-
1.70) 
 543 
Data is presented as dAdjusted Odds Ratio (95% Confidence Interval) - Adjusted for: sex, 544 
maternal age and BMI, ethnicity, parity, smoking status, and mode of birth. ap-value < 0.05; 545 
bp-value <0.01; cp-value <0.001 546 
 547 
AGA: appropriate for gestational age (birthweight 10th-90th centile); NA, not applicable; 548 
NICU: neonatal intensive care unit; SGA: small for gestational age (birthweight <10th centile 549 
for gestational age); SGA1: birthweight 5th - <10th centiles for gender and gestational age; 550 
SGA2: birthweight <5th centile for gestational age; NICU: Neonatal Intensive Care Unit; 551 
SCNM: Serious Composite Neonatal Morbidity  552 
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Figure 1: Participant flow diagram 554 
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